Related Experiment Video
Updated: Aug 2, 2026

The Influence of Liver Resection on Intrahepatic Tumor Growth
Published on: April 9, 2016
Liver tumor formation in female rat induced by fluopyram is mediated by CAR/PXR nuclear receptor activation
H Tinwell1, D Rouquié1, F Schorsch1
1Bayer SAS, 16 Rue Jean-Marie Leclair, 69009 Lyon, France.
Abstract:
Fluopyram is a broad spectrum fungicide targeting plant pathogenic fungi (eg. white dot, black mold, botrytis). During the general toxicity evaluation of fluopyram in rodents, the liver was identified as a target organ (hepatomegaly and liver hypertrophy were observed in all studies). At the end of the guideline carcinogenicity study, an increased incidence of hepatocellular adenomas and carcinomas was observed in female Wistar rats following exposure to the highest fluopyram dose evaluated (1500ppm). Short-term mechanistic studies (3, 7 or 28days of exposure) were conducted in the female rat to identify the initial key events responsible for the tumor formation and to establish thresholds for each of the early hepatic changes. Increased expression of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) inducible genes was recorded after each exposure period. Further confirmation of CAR/PXR activation was provided by increased activity of specific Phase I enzymes (PROD/BROD respectively). Increased hepatocellular proliferation (measured by Ki67) was observed after each exposure period with the greatest proliferative response occurring after 3days of treatment. In these studies, dose responses and clear thresholds were established for gene expression, enzyme activity and cell proliferation. Furthermore, these early hepatic changes were shown to be reversible following compound withdrawal. Other modes of action for liver tumor formation such as DNA damage, cytotoxicity and peroxisome proliferation were excluded during the investigations. In conclusion, fluopyram is a threshold carcinogen and the resultant hepatocellular carcinomas in the female rat are due to hepatocellular proliferation mediated by CAR/PXR activation.
Insights
Fluopyram causes liver tumors in female rats through a threshold mechanism involving liver cell proliferation. These effects are reversible and linked to constitutive androstane receptor (CAR) and pregnane X receptor (PXR) activation.
Area of Science:
- Toxicology
- Carcinogenesis
- Molecular Biology
Background:
- Fluopyram, a broad-spectrum fungicide, targets plant pathogenic fungi.
- Hepatomegaly and liver hypertrophy were observed in rodent toxicity studies, identifying the liver as a target organ.
- Increased hepatocellular adenomas and carcinomas were noted in female Wistar rats at the highest fluopyram dose in a carcinogenicity study.
Purpose of the Study:
- To identify key early events leading to liver tumor formation in female rats exposed to fluopyram.
- To establish dose-response relationships and thresholds for early hepatic changes.
- To investigate the reversibility of these hepatic changes upon compound withdrawal.
Main Methods:
- Short-term (3, 7, 28 days) mechanistic studies in female rats.
- Assessment of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) activation markers.
- Measurement of Phase I enzyme activity (PROD/BROD) and hepatocellular proliferation (Ki67).
Main Results:
- Increased expression of CAR and PXR inducible genes and elevated Phase I enzyme activity were observed after fluopyram exposure.
- Significant hepatocellular proliferation (Ki67) was detected, with the highest response after 3 days of treatment.
- Dose-response relationships and clear thresholds were established for gene expression, enzyme activity, and cell proliferation, which were reversible upon withdrawal.
Conclusions:
- Fluopyram is a threshold carcinogen, inducing liver tumors via CAR/PXR-mediated hepatocellular proliferation.
- The identified early hepatic changes and subsequent tumor formation are dependent on dose and reversible.
- Mechanisms such as DNA damage, cytotoxicity, and peroxisome proliferation were excluded as modes of action for fluopyram-induced liver tumors.

